Dopamine receptor homooligomers and heterooligomers in schizophrenia.

摘要: Over the past two decades dopamine D2 receptor has been undoubtedly most widely studied for therapeutic treatment of schizophrenia, as majority antipsychotics exhibit antagonism at this receptor. However, cognitive symptoms disorder are mostly resistant to available antipsychotic treatments and, a result, there is critical need develop novel therapies that ameliorate all symptoms. The recognition receptors, such G protein-coupled receptors (GPCRs), exist oligomeric complexes provided new avenues drug design in search therapies. Furthermore, it now known can form heteromers, D1-D2 heteromer, with pharmacology and function distinct from its constituent significantly expanded range potential targets. aim review discuss relevance these oligomers schizophrenia address value heteromers strategies.